Company Overview and News

 
LAUGFS Gas Partners with Colombo City Centre as its exclusive LPG service provider

2018-08-17 lankabusinessonline
LAUGFS Gas has come into an exclusive arrangement with Colombo City Centre’s upcoming mall to provide LPG to all its restaurants and food outlets. With the development of Sri Lanka’s first Board of Investment (BOI) approved mixed-use development project, LAUGFS Gas, the only private sector energy player in the local LPG market, recently announced a partnership with the Colombo City Centre mall.
LGL

 
Laugfs Gas urges Govt to introduce transparent mechanism for pricing LPG retail price

2018-05-18 lankabusinessonline
May 18, 2018 (LBO) – Sri Lanka’s liquid petroleum gas (LPG) prices should be adjusted using a pricing mechanism that is transparent, impartial and fair, Laugfs Gas said issuing a statement.
LGL

 
Anantaya Pasikudah wins Booking.com guest review award

2018-05-03 lankabusinessonline
(PRESS RELEASE) – Anantaya Resort & Spa Pasikudah was recently awarded the Booking.com Guest Review Award. Offering unique experiences and exceptional service, Anantaya Pasikudah was rated a high standard property on Booking.com with an outstanding score of over nine.
LGL

 
LAUGFS excel at CMI management excellence awards

2018-04-24 lankabusinessonline
Reinforcing the leadership force that drives LAUGFS, Lfinity – Chief Operating Officer (COO), Muditha Thebuwana and LAUGFS Gas – Deputy General Manager, Kaushala Amarasekara emerged winners at the Chartered Management Institute Management Excellence Awards (CMI-MEA) 2017 held recently. While Muditha was bestowed the “Most Innovative Manager” award in the Service Sector – Small and Medium, Kaushala clinched the award for “Best Emerging Manager” in the Industrial Sector – Large Category.
LGL

 
LAUGFS leaders excel at CMI management excellence awards 2017

2018-04-20 lankabusinessonline
Reinforcing the leadership force that drives LAUGFS, Lfinity – Chief Operating Officer (COO), Muditha Thebuwana and LAUGFS Gas – Deputy General Manager, Kaushala Amarasekara emerged winners at the Chartered Management Institute Management Excellence Awards (CMI-MEA) 2017 held recently. While Muditha was bestowed the “Most Innovative Manager” award in the Service Sector – Small and Medium, Kaushala clinched the award for “Best Emerging Manager” in the Industrial Sector – Large Category.
LGL

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CSE:LGL / LAUGFS GAS PLC on message board site Silicon Investor.

SLGLF - Silverado Gold Mines Limited SLGLF - Silverado Gold Mines Limited SLGLF - Silverado Gold Mines Limited